Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	GTPase activator activity	ADGRB3 AGAP11 AGAP7P AGAP4 AGAP6	2.01e-04	279	39	5	GO:0005096
GeneOntologyMolecularFunction	single-stranded DNA endodeoxyribonuclease activity	ERCC1 POLQ	2.86e-04	13	39	2	GO:0000014
GeneOntologyMolecularFunction	methylated histone binding	PWWP2A BPTF KMT2E	6.30e-04	86	39	3	GO:0035064
GeneOntologyMolecularFunction	methylation-dependent protein binding	PWWP2A BPTF KMT2E	6.74e-04	88	39	3	GO:0140034
GeneOntologyMolecularFunction	modification-dependent protein binding	PWWP2A BPTF KMT2E PML	6.82e-04	206	39	4	GO:0140030
GeneOntologyMolecularFunction	catalytic activity, acting on a nucleic acid	BPTF TRMT10C ERCC1 MLH3 PDE12 POLQ	1.46e-03	645	39	6	GO:0140640
GeneOntologyMolecularFunction	catalytic activity, acting on DNA	BPTF ERCC1 MLH3 POLQ	1.66e-03	262	39	4	GO:0140097
GeneOntologyMolecularFunction	histone binding	PWWP2A BPTF PHC3 KMT2E	1.73e-03	265	39	4	GO:0042393
GeneOntologyMolecularFunction	ATP-dependent activity, acting on DNA	BPTF MLH3 POLQ	1.94e-03	127	39	3	GO:0008094
GeneOntologyMolecularFunction	nucleoside-triphosphatase regulator activity	ADGRB3 AGAP11 AGAP7P AGAP4 AGAP6	2.92e-03	507	39	5	GO:0060589
GeneOntologyMolecularFunction	GTPase regulator activity	ADGRB3 AGAP11 AGAP7P AGAP4 AGAP6	2.92e-03	507	39	5	GO:0030695
GeneOntologyMolecularFunction	DNA endonuclease activity	ERCC1 POLQ	3.34e-03	44	39	2	GO:0004520
GeneOntologyMolecularFunction	ribonucleoside triphosphate phosphatase activity	MLH3 AGAP11 AGAP7P POLQ AGAP4 AGAP6	3.66e-03	775	39	6	GO:0017111
GeneOntologyMolecularFunction	GTPase activity	AGAP11 AGAP7P AGAP4 AGAP6	4.29e-03	341	39	4	GO:0003924
GeneOntologyMolecularFunction	pyrophosphatase activity	MLH3 AGAP11 AGAP7P POLQ AGAP4 AGAP6	5.39e-03	839	39	6	GO:0016462
GeneOntologyMolecularFunction	hydrolase activity, acting on acid anhydrides	MLH3 AGAP11 AGAP7P POLQ AGAP4 AGAP6	5.42e-03	840	39	6	GO:0016817
GeneOntologyMolecularFunction	hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides	MLH3 AGAP11 AGAP7P POLQ AGAP4 AGAP6	5.42e-03	840	39	6	GO:0016818
MousePheno	fused cornea and lens	AGAP11 AGAP7P AGAP4 AGAP6	2.64e-07	24	33	4	MP:0001307
MousePheno	abnormal lens development	AGAP11 AGAP7P AGAP4 AGAP6	3.25e-05	78	33	4	MP:0005545
MousePheno	absent pinna reflex	AGAP11 AGAP7P AGAP4 AGAP6	5.46e-05	89	33	4	MP:0006358
MousePheno	abnormal pinna reflex	AGAP11 AGAP7P AGAP4 AGAP6	8.94e-05	101	33	4	MP:0001485
MousePheno	increased circulating potassium level	AGAP11 AGAP7P AGAP4 AGAP6	1.80e-04	121	33	4	MP:0005627
Domain	ArfGap	AGAP11 AGAP7P AGAP4 AGAP6	3.71e-07	29	39	4	SM00105
Domain	ARFGAP	AGAP11 AGAP7P AGAP4 AGAP6	3.71e-07	29	39	4	PS50115
Domain	ArfGAP	AGAP11 AGAP7P AGAP4 AGAP6	3.71e-07	29	39	4	IPR001164
Domain	ArfGap	AGAP11 AGAP7P AGAP4 AGAP6	3.71e-07	29	39	4	PF01412
Domain	IGc2	NPHS1 TMIGD1 CD4 ALPK2	1.42e-03	235	39	4	SM00408
Domain	Ig_sub2	NPHS1 TMIGD1 CD4 ALPK2	1.42e-03	235	39	4	IPR003598
Domain	ANK	AGAP11 AGAP7P AGAP4 AGAP6	1.81e-03	251	39	4	SM00248
Domain	ANK_REPEAT	AGAP11 AGAP7P AGAP4 AGAP6	1.86e-03	253	39	4	PS50088
Domain	Ankyrin_rpt-contain_dom	AGAP11 AGAP7P AGAP4 AGAP6	1.89e-03	254	39	4	IPR020683
Domain	ANK_REP_REGION	AGAP11 AGAP7P AGAP4 AGAP6	1.89e-03	254	39	4	PS50297
Domain	Ankyrin_rpt	AGAP11 AGAP7P AGAP4 AGAP6	2.12e-03	262	39	4	IPR002110
Domain	GPS	ADGRB3 ADGRG4	2.29e-03	34	39	2	SM00303
Domain	GPCR_2_secretin-like_CS	ADGRB3 ADGRG4	2.29e-03	34	39	2	IPR017983
Domain	GPS	ADGRB3 ADGRG4	2.42e-03	35	39	2	PF01825
Domain	GPS	ADGRB3 ADGRG4	2.56e-03	36	39	2	PS50221
Domain	PH	AGAP11 AGAP7P AGAP4 AGAP6	2.62e-03	278	39	4	SM00233
Domain	PH_DOMAIN	AGAP11 AGAP7P AGAP4 AGAP6	2.66e-03	279	39	4	PS50003
Domain	PH_domain	AGAP11 AGAP7P AGAP4 AGAP6	2.69e-03	280	39	4	IPR001849
Domain	GPS	ADGRB3 ADGRG4	2.70e-03	37	39	2	IPR000203
Domain	G_PROTEIN_RECEP_F2_1	ADGRB3 ADGRG4	3.15e-03	40	39	2	PS00649
Domain	G_PROTEIN_RECEP_F2_3	ADGRB3 ADGRG4	3.15e-03	40	39	2	PS50227
Domain	GPCR_2_extracellular_dom	ADGRB3 ADGRG4	3.15e-03	40	39	2	IPR001879
Domain	G_PROTEIN_RECEP_F2_2	ADGRB3 ADGRG4	4.89e-03	50	39	2	PS00650
Domain	7tm_2	ADGRB3 ADGRG4	4.89e-03	50	39	2	PF00002
Domain	GPCR_2-like	ADGRB3 ADGRG4	6.97e-03	60	39	2	IPR017981
Domain	GPCR_2_secretin-like	ADGRB3 ADGRG4	6.97e-03	60	39	2	IPR000832
Domain	G_PROTEIN_RECEP_F2_4	ADGRB3 ADGRG4	7.19e-03	61	39	2	PS50261
Domain	Ig_I-set	NPHS1 TMIGD1 ALPK2	7.24e-03	190	39	3	IPR013098
Domain	ig	NPHS1 TMIGD1 CD4	7.24e-03	190	39	3	PF00047
Domain	Immunoglobulin	NPHS1 TMIGD1 CD4	7.24e-03	190	39	3	IPR013151
Domain	I-set	NPHS1 TMIGD1 ALPK2	7.24e-03	190	39	3	PF07679
Domain	Zinc_finger_PHD-type_CS	BPTF KMT2E	8.13e-03	65	39	2	IPR019786
Domain	Ank_2	AGAP11 AGAP4 AGAP6	1.01e-02	215	39	3	PF12796
Domain	PHD	BPTF KMT2E	1.07e-02	75	39	2	PF00628
Pathway	REACTOME_REGULATION_OF_PTEN_LOCALIZATION	PML NEDD4	1.26e-04	9	27	2	M27814
Pathway	REACTOME_REGULATION_OF_PTEN_LOCALIZATION	PML NEDD4	1.57e-04	10	27	2	MM15539
Pubmed	GGAPs, a new family of bifunctional GTP-binding and GTPase-activating proteins.	AGAP11 AGAP7P AGAP4 AGAP6	1.69e-10	9	39	4	12640130
Pubmed	AGAP1/AP-3-dependent endocytic recycling of M5 muscarinic receptors promotes dopamine release.	AGAP11 AGAP7P AGAP4 AGAP6	2.82e-10	10	39	4	20664521
Pubmed	AGAP1, a novel binding partner of nitric oxide-sensitive guanylyl cyclase.	AGAP11 AGAP7P AGAP4 AGAP6	4.43e-10	11	39	4	15381706
Pubmed	The Endosome Localized Arf-GAP AGAP1 Modulates Dendritic Spine Morphology Downstream of the Neurodevelopmental Disorder Factor Dysbindin.	AGAP11 AGAP7P AGAP4 AGAP6	9.58e-10	13	39	4	27713690
Pubmed	GTP-binding protein-like domain of AGAP1 is protein binding site that allosterically regulates ArfGAP protein catalytic activity.	AGAP11 AGAP7P AGAP4 AGAP6	1.34e-09	14	39	4	22453919
Pubmed	Synaptic GAP and GEF Complexes Cluster Proteins Essential for GTP Signaling.	DLGAP1 AGAP11 CAND1 AGAP7P AGAP4 AGAP6 NEDD4	2.57e-08	281	39	7	28706196
Pubmed	PML tumor suppressor is regulated by HIPK2-mediated phosphorylation in response to DNA damage.	HIPK2 PML	1.23e-06	2	39	2	19015637
Pubmed	Characterization of an exchangeable gene trap using pU-17 carrying a stop codon-beta geo cassette.	BPTF TRMT10C AGAP11 AGAP7P AGAP4 AGAP6 NEDD4	1.99e-06	536	39	7	15840001
Pubmed	Exchangeable gene trap using the Cre/mutated lox system.	BPTF TRMT10C AGAP11 AGAP7P AGAP4 AGAP6 NEDD4	2.04e-06	538	39	7	10512203
Pubmed	PML is required for homeodomain-interacting protein kinase 2 (HIPK2)-mediated p53 phosphorylation and cell cycle arrest but is dispensable for the formation of HIPK domains.	HIPK2 PML	3.67e-06	3	39	2	12907596
Pubmed	The TRIM9/TRIM67 neuronal interactome reveals novel activators of morphogenesis.	DLGAP1 AGAP11 AGAP7P AGAP4 AGAP6	4.47e-06	218	39	5	33378226
Pubmed	Comprehensive Interactome Mapping of the DNA Repair Scaffold SLX4 Using Proximity Labeling and Affinity Purification.	ZNF106 ERCC1 MLH3 POLQ PML	4.89e-06	222	39	5	37071664
Pubmed	Role of the SUMO-interacting motif in HIPK2 targeting to the PML nuclear bodies and regulation of p53.	HIPK2 PML	7.34e-06	4	39	2	21192925
Pubmed	SUMOylation-dependent localization of IKKepsilon in PML nuclear bodies is essential for protection against DNA-damage-triggered cell death.	HIPK2 PML	7.34e-06	4	39	2	20188669
Pubmed	Two Nedd4-binding motifs underlie modulation of sodium channel Nav1.6 by p38 MAPK.	CD4 NEDD4	7.34e-06	4	39	2	20530479
Pubmed	AXIN is an essential co-activator for the promyelocytic leukemia protein in p53 activation.	HIPK2 PML	1.22e-05	5	39	2	21057547
Pubmed	Functional impairment of the HIPK2 small ubiquitin-like modifier (SUMO)-interacting motif in acute myeloid leukemia.	HIPK2 PML	1.22e-05	5	39	2	30755814
Pubmed	Control of nuclear HIPK2 localization and function by a SUMO interaction motif.	HIPK2 PML	1.83e-05	6	39	2	21145359
Pubmed	Homeodomain-interacting protein kinase 1 modulates Daxx localization, phosphorylation, and transcriptional activity.	HIPK2 PML	1.83e-05	6	39	2	12529400
Pubmed	PML activates transcription by protecting HIPK2 and p300 from SCFFbx3-mediated degradation.	HIPK2 PML	2.56e-05	7	39	2	18809579
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: III. the complete nucleotide sequences of 500 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	ADGRB3 AGAP11 CAND1 AGAP7P AGAP4 AGAP6	2.56e-05	529	39	6	14621295
Pubmed	Impaired function of primitive hematopoietic cells in mice lacking the Mixed-Lineage-Leukemia homolog MLL5.	CD4 KMT2E	3.42e-05	8	39	2	18952892
Pubmed	SUMO5, a Novel Poly-SUMO Isoform, Regulates PML Nuclear Bodies.	HIPK2 PML	3.42e-05	8	39	2	27211601
Pubmed	Intact prostaglandin signaling through EP2 and EP4 receptors in stromal progenitor cells is required for normal development of the renal cortex in mice.	NPHS1 PTGER2	1.11e-04	14	39	2	35037469
Pubmed	Ex vivo Quantitative Proteomic Analysis of Serotonin Transporter Interactome: Network Impact of the SERT Ala56 Coding Variant.	DLGAP1 AGAP11 AGAP7P AGAP4 AGAP6	1.15e-04	430	39	5	32581705
Pubmed	Genetic polymorphisms in 85 DNA repair genes and bladder cancer risk.	ERCC1 MLH3 POLQ	1.17e-04	84	39	3	19237606
Pubmed	Reverse two-hybrid screening to analyze protein-protein interaction of HIV-1 viral and cellular proteins.	CD4 NEDD4	1.27e-04	15	39	2	19020832
Pubmed	A transposon in Comt generates mRNA variants and causes widespread expression and behavioral differences among mice.	HIPK2 DLGAP1	1.65e-04	17	39	2	20808911
Pubmed	HIV-1 Nef down-modulates C-C and C-X-C chemokine receptors via ubiquitin and ubiquitin-independent mechanism.	CD4 NEDD4	1.65e-04	17	39	2	24489825
Pubmed	New interaction partners for Nek4.1 and Nek4.2 isoforms: from the DNA damage response to RNA splicing.	HYAL4 AGAP7P AGAP4 ALPK2 PML	2.61e-04	513	39	5	25798074
Pubmed	Proliferating cell nuclear antigen (PCNA)-binding protein C1orf124 is a regulator of translesion synthesis.	ERCC1 CAND1	2.79e-04	22	39	2	22902628
Pubmed	Oncogenic functions of protein kinase D2 and D3 in regulating multiple cancer-related pathways in breast cancer.	AGAP11 AGAP4 AGAP6	3.03e-04	116	39	3	30652415
Pubmed	A gene-based risk score for lung cancer susceptibility in smokers and ex-smokers.	ERCC1 MLH3 PTGER2	3.43e-04	121	39	3	19789190
Pubmed	Genetic variation in immune regulation and DNA repair pathways and stomach cancer in China.	ERCC1 POLQ	4.55e-04	28	39	2	19661089
Pubmed	The human and mouse repertoire of the adhesion family of G-protein-coupled receptors.	ADGRB3 ADGRG4	4.88e-04	29	39	2	15203201
Pubmed	International Union of Basic and Clinical Pharmacology. XCIV. Adhesion G protein-coupled receptors.	ADGRB3 ADGRG4	6.33e-04	33	39	2	25713288
Pubmed	alphaII-Spectrin interacts with five groups of functionally important proteins in the nucleus.	ERCC1 PML	6.72e-04	34	39	2	16889989
Pubmed	Development of an efficient screening system to identify novel bone metabolism-related genes using the exchangeable gene trap mutagenesis mouse models.	BPTF NEDD4	7.12e-04	35	39	2	28106071
Pubmed	An investigation into the human serum "interactome".	NPHS1 PHC3 PDZRN4	8.02e-04	162	39	3	15174051
Pubmed	Defining the molecular character of the developing and adult kidney podocyte.	NPHS1 EYA4	8.84e-04	39	39	2	21931791
Pubmed	Identification of new ciliary signaling pathways in the brain and insights into neurological disorders.	AGAP11 AGAP7P AGAP4 AGAP6	1.08e-03	405	39	4	38187761
Cytoband	Ensembl 112 genes in cytogenetic band chr15q24	PML CCDC33 SCAPER	1.56e-04	122	39	3	chr15q24
Cytoband	10q11.23	AGAP7P AGAP6	3.65e-04	33	39	2	10q11.23
Cytoband	Ensembl 112 genes in cytogenetic band chr10q11	AGAP7P AGAP4 AGAP6	5.54e-04	188	39	3	chr10q11
Cytoband	Xq26.3	ZNF75D ADGRG4	1.50e-03	67	39	2	Xq26.3
GeneFamily	ArfGAPs	AGAP11 AGAP7P AGAP4 AGAP6	2.79e-07	33	31	4	395
GeneFamily	X-linked mental retardation\|Rho GTPase activating proteins\|BAR-PH domain containing	AGAP11 AGAP4 AGAP6	3.05e-06	17	31	3	1291
GeneFamily	Ankyrin repeat domain containing	AGAP11 AGAP7P AGAP4 AGAP6	7.42e-04	242	31	4	403
GeneFamily	C2-set domain containing\|Immunoglobulin like domain containing\|Scavenger receptors	NPHS1 CD4	2.13e-03	40	31	2	592
GeneFamily	Pleckstrin homology domain containing\|Rho guanine nucleotide exchange factors\|C2 domain containing	AGAP7P AGAP4 AGAP6	5.18e-03	206	31	3	682
GeneFamily	Zinc fingers C2H2-type\|ZF class homeoboxes and pseudogenes	ZNF75D ZHX3 ZNF106 ZNF141 SCAPER	7.02e-03	718	31	5	28
GeneFamily	PHD finger proteins	BPTF KMT2E	1.04e-02	90	31	2	88
Coexpression	THEODOROU_MAMMARY_TUMORIGENESIS	AGAP11 AGAP7P AGAP4 AGAP6	2.67e-07	37	39	4	MM1121
Coexpression	GAUSSMANN_MLL_AF4_FUSION_TARGETS_F_DN	AGAP11 AGAP7P AGAP4 AGAP6	5.44e-07	44	39	4	MM485
Coexpression	KARLSSON_TGFB1_TARGETS_DN	AGAP11 AGAP7P KMT2E AGAP4 AGAP6	1.42e-05	209	39	5	MM1058
Coexpression	CHYLA_CBFA2T3_TARGETS_DN	EYA4 AGAP11 AGAP7P AGAP4 AGAP6	4.27e-05	263	39	5	MM1295
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal--glomerular_mesenchymal_cell-Renin-positive_Juxtaglomerular_Granular_Cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ADGRB3 CD4 PTGER2 PDZRN4	1.27e-05	164	39	4	43630a448f4369fa9e4e3eccdf3b9f29cec16c39
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ADGRB3 CD4 PTGER2 PDZRN4	1.27e-05	164	39	4	108fbecb56d69a675d6ce6e826a873ae528f2fd7
ToppCell	renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal--glomerular_mesenchymal_cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ADGRB3 CD4 PTGER2 PDZRN4	1.27e-05	164	39	4	46208f18325976c89f572f6627aea0582142b92d
ToppCell	Neuron-Postmitotic-Excitatory_Neuron_-Newborn-35\|World / Primary Cells by Cluster	BPTF DLGAP1 KMT2E PDZRN4	2.65e-05	198	39	4	de5214a85fe017eb23d4aa8af624464f062ec57e
Drug	Clioquinol [130-26-7]; Up 200; 13uM; MCF7; HT_HG-U133A	ADGRB3 CD4 PDE12 PML SCAPER	1.80e-05	191	39	5	6461_UP
Drug	Antimycin A [1397-94-0]; Down 200; 7.2uM; PC3; HT_HG-U133A	HIPK2 ZHX3 ERCC1 PML SCAPER	1.99e-05	195	39	5	5053_DN
Drug	Althiazide [5588-16-9]; Down 200; 10.4uM; PC3; HT_HG-U133A	ZNF75D EYA4 PDE12 PML SCAPER	2.04e-05	196	39	5	4491_DN
Drug	Cloxacillin sodium salt [642-78-4]; Down 200; 8.8uM; PC3; HT_HG-U133A	BPTF ZNF75D ERCC1 ZNF141 PML	2.09e-05	197	39	5	2126_DN
Drug	Rolipram [61413-54-5]; Up 200; 14.6uM; MCF7; HT_HG-U133A	HIPK2 CD4 PDE12 PML SCAPER	2.09e-05	197	39	5	6449_UP
Drug	Memantine Hydrochloride [41100-52-1]; Up 200; 18.6uM; MCF7; HT_HG-U133A	HIPK2 ZHX3 CD4 PDE12 SCAPER	2.09e-05	197	39	5	7354_UP
Drug	Lisinopril [83915-83-7]; Up 200; 9uM; MCF7; HT_HG-U133A	NPHS1 MLH3 PDE12 PML SCAPER	2.19e-05	199	39	5	5504_UP
Drug	2-Aminobenzenesulfonamide [3306-62-5]; Down 200; 23.2uM; PC3; HT_HG-U133A	ZNF75D PHC3 ZNF141 MLH3 PML	2.19e-05	199	39	5	6321_DN
Drug	Meprylcaine hydrochloride [956-03-6]; Up 200; 14.8uM; HL60; HT_HG-U133A	MLH3 PDE12 SLCO1C1 PML PDZRN4	2.25e-05	200	39	5	6123_UP
Drug	Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A	HIPK2 BPTF ZHX3 PHC3	2.01e-04	170	39	4	3791_DN
Drug	Prenylamine lactate [69-43-2]; Up 200; 9.6uM; MCF7; HT_HG-U133A	ZNF75D DLGAP1 CDKN2AIP PML	2.45e-04	179	39	4	5489_UP
Drug	Adenosine 5'-monophosphate monohydrate [18422-05-4]; Down 200; 11uM; HL60; HG-U133A	HIPK2 EDEM3 ERCC1 PTGER2	2.95e-04	188	39	4	1622_DN
Drug	Thiostrepton [1393-48-2]; Down 200; 2.4uM; PC3; HT_HG-U133A	HIPK2 MLH3 PML SCAPER	3.14e-04	191	39	4	4563_DN
Drug	Vincamine [1617-90-9]; Down 200; 11.2uM; MCF7; HT_HG-U133A	ZHX3 PDE12 SLCO1C1 SCAPER	3.14e-04	191	39	4	3976_DN
Drug	Forskolin, from Coleus forskohlii; Down 200; 0.5uM; PC3; HT_HG-U133A	HIPK2 MLH3 PDE12 PTGER2	3.20e-04	192	39	4	7104_DN
Drug	C75; Down 200; 10uM; MCF7; HT_HG-U133A	HIPK2 NPHS1 PDE12 PML	3.26e-04	193	39	4	6394_DN
Drug	Norfloxacin [70458-96-7]; Down 200; 12.6uM; MCF7; HT_HG-U133A	HIPK2 ZNF75D PHC3 SCAPER	3.26e-04	193	39	4	5985_DN
Drug	Metoprolol-(+,-) (+)-tartrate salt [56392-17-7]; Up 200; 5.8uM; MCF7; HT_HG-U133A	HIPK2 PDE12 PML SCAPER	3.26e-04	193	39	4	6846_UP
Drug	0297417-0002B [362658-29-5]; Down 200; 10uM; PC3; HT_HG-U133A	EYA4 POLQ PTGER2 PML	3.33e-04	194	39	4	6895_DN
Drug	Beta-Escin [11072-93-8]; Down 200; 3.2uM; PC3; HT_HG-U133A	HIPK2 EDEM3 ZNF75D PML	3.33e-04	194	39	4	3807_DN
Drug	Cyproterone acetate [427-51-0]; Down 200; 9.6uM; HL60; HT_HG-U133A	HIPK2 MLH3 PDE12 PML	3.33e-04	194	39	4	6124_DN
Drug	Graveoline [485-61-0]; Down 200; 14.4uM; MCF7; HT_HG-U133A	PHC3 ZNF141 PDE12 PML	3.33e-04	194	39	4	4738_DN
Drug	Cyproterone acetate [427-51-0]; Down 200; 9.6uM; PC3; HT_HG-U133A	HIPK2 PHC3 PDE12 SCAPER	3.33e-04	194	39	4	4470_DN
Drug	Equilin [474-86-2]; Down 200; 15uM; MCF7; HT_HG-U133A	ZNF141 PTGER2 PML SCAPER	3.33e-04	194	39	4	5620_DN
Drug	Sulfacetamide sodic hydrate [6209-17-2]; Down 200; 15.8uM; HL60; HT_HG-U133A	HIPK2 ZNF75D PML SCAPER	3.39e-04	195	39	4	1859_DN
Drug	Acenocoumarol [152-72-7]; Up 200; 11.4uM; PC3; HT_HG-U133A	ZNF75D PHC3 PTGER2 PML	3.39e-04	195	39	4	5878_UP
Drug	Atractyloside potassium salt [102130-43-8]; Up 200; 5uM; PC3; HT_HG-U133A	ZNF75D ZNF141 MLH3 CD4	3.39e-04	195	39	4	7393_UP
Drug	Oxymetazoline hydrochloride [2315-02-8]; Down 200; 13.4uM; MCF7; HT_HG-U133A	HIPK2 EDEM3 PML SCAPER	3.39e-04	195	39	4	2278_DN
Drug	Nafronyl oxalate [3200-06-4]; Down 200; 8.4uM; HL60; HT_HG-U133A	PHC3 CD4 PML SCAPER	3.39e-04	195	39	4	1267_DN
Drug	Thiamphenicol [15318-45-3]; Down 200; 11.2uM; HL60; HT_HG-U133A	ZNF75D ERCC1 PML SCAPER	3.39e-04	195	39	4	1867_DN
Drug	Clindamycin hydrochloride [21462-39-5]; Down 200; 8.6uM; MCF7; HT_HG-U133A	HIPK2 ZHX3 PHC3 MLH3	3.39e-04	195	39	4	7172_DN
Drug	2-butenal	HIPK2 PWWP2A BPTF ZHX3	3.39e-04	195	39	4	ctd:C012796
Drug	Naringenine [480-41-1]; Down 200; 14.6uM; PC3; HT_HG-U133A	HIPK2 ZHX3 EYA4 SCAPER	3.39e-04	195	39	4	4597_DN
Drug	CP-863187 [668981-07-5]; Up 200; 10uM; PC3; HT_HG-U133A	NPHS1 PDE12 SLCO1C1 PML	3.46e-04	196	39	4	7512_UP
Drug	Indomethacin [53-86-1]; Up 200; 11.2uM; MCF7; HT_HG-U133A	ERCC1 ZNF141 PML SCAPER	3.46e-04	196	39	4	7409_UP
Drug	nordihydroguaiaretic acid; Down 200; 1uM; HL60; HT_HG-U133A	ZHX3 MLH3 PDE12 PML	3.46e-04	196	39	4	6182_DN
Drug	Alcuronium chloride [15180-03-7]; Up 200; 5.4uM; MCF7; HT_HG-U133A	HIPK2 PTGER2 PML CCDC33	3.46e-04	196	39	4	4409_UP
Drug	Apomorphine hydrochloride hemihydrate [41372-20-7]; Up 200; 6.4uM; MCF7; HT_HG-U133A	EYA4 OPN1SW PML SCAPER	3.46e-04	196	39	4	1505_UP
Drug	Stachydrine hydrochloride; Down 200; 22.2uM; PC3; HT_HG-U133A	PHC3 PDE12 PML NEDD4	3.46e-04	196	39	4	4469_DN
Drug	Isoniazid [54-85-3]; Down 200; 29.2uM; MCF7; HT_HG-U133A	HIPK2 ZNF75D PHC3 PDE12	3.53e-04	197	39	4	7197_DN
Drug	clozapine; Up 200; 10uM; MCF7; HT_HG-U133A	CD4 PTGER2 PML SCAPER	3.53e-04	197	39	4	6988_UP
Drug	Crotamiton [483-63-6]; Down 200; 19.6uM; MCF7; HT_HG-U133A	ZNF75D ZHX3 PML SCAPER	3.53e-04	197	39	4	5689_DN
Drug	Methylhydantoin-5-(D) [55147-68-7]; Down 200; 35uM; HL60; HT_HG-U133A	PDE12 PML CCDC33 SCAPER	3.53e-04	197	39	4	2994_DN
Drug	Letrozole [112809-51-5]; Up 200; 14uM; PC3; HT_HG-U133A	ADGRB3 ZHX3 ZNF141 PML	3.53e-04	197	39	4	4240_UP
Drug	Cephapirin sodium salt [24356-60-3]; Up 200; 9uM; PC3; HT_HG-U133A	ZNF75D PHC3 MLH3 PDE12	3.53e-04	197	39	4	7142_UP
Drug	0198306-0000 [212631-61-3]; Up 200; 10uM; PC3; HT_HG-U133A	ERCC1 MLH3 PML SCAPER	3.53e-04	197	39	4	7069_UP
Drug	Ginkgolide A [15291-75-5]; Up 200; 9.8uM; HL60; HT_HG-U133A	HIPK2 ZNF75D ZHX3 PML	3.53e-04	197	39	4	1324_UP
Drug	Tropicamide [1508-75-4]; Down 200; 14uM; MCF7; HT_HG-U133A	HIPK2 PHC3 PDE12 PML	3.53e-04	197	39	4	4744_DN
Drug	(-)-Eseroline fumarate salt [104015-29-4]; Up 200; 12uM; PC3; HT_HG-U133A	ZHX3 ERCC1 MLH3 PML	3.53e-04	197	39	4	7267_UP
Drug	L(-)-vesamicol hydrochloride [112709-59-8]; Up 200; 13.6uM; MCF7; HT_HG-U133A	ZNF75D PHC3 DLGAP1 PML	3.53e-04	197	39	4	6497_UP
Drug	Ampyrone [83-07-8]; Up 200; 19.6uM; MCF7; HT_HG-U133A	ADGRB3 PHC3 CD4 PML	3.53e-04	197	39	4	2249_UP
Drug	Pirenperone [ 75444-65-4]; Down 200; 10.2uM; PC3; HT_HG-U133A	EYA4 CD4 PML SCAPER	3.53e-04	197	39	4	4679_DN
Drug	Raloxifene hydrochloride [82640-04-8]; Down 200; 7.8uM; HL60; HT_HG-U133A	HIPK2 ZNF75D PHC3 PML	3.53e-04	197	39	4	2738_DN
Drug	Ceforanide [60925-61-3]; Down 200; 7.6uM; MCF7; HT_HG-U133A	EDEM3 ZHX3 CD4 SCAPER	3.53e-04	197	39	4	3309_DN
Drug	Mephenytoin [50-12-4]; Down 200; 18.4uM; PC3; HT_HG-U133A	ZNF75D EYA4 PDE12 PML	3.53e-04	197	39	4	5801_DN
Drug	Flavoxate hydrochloride [3717-88-2]; Up 200; 9.4uM; HL60; HT_HG-U133A	ZHX3 PML CCDC33 SCAPER	3.60e-04	198	39	4	2373_UP
Drug	Loracarbef [121961-22-6]; Down 200; 10.8uM; MCF7; HT_HG-U133A	HIPK2 ZHX3 ZNF141 MLH3	3.60e-04	198	39	4	5492_DN
Drug	Methimazole [60-56-0]; Up 200; 35uM; PC3; HT_HG-U133A	ZNF75D ZHX3 PHC3 ZNF141	3.60e-04	198	39	4	4550_UP
Drug	Acetazolamide [59-66-5]; Up 200; 18uM; HL60; HT_HG-U133A	HIPK2 MLH3 SLCO1C1 PML	3.60e-04	198	39	4	1850_UP
Drug	estradiol, USP; Up 200; 0.1uM; MCF7; HT_HG-U133A	HIPK2 ZHX3 PDE12 SCAPER	3.60e-04	198	39	4	6968_UP
Drug	(R)-Propranolol hydrochloride [13071-11-9]; Up 200; 13.6uM; PC3; HT_HG-U133A	HYAL4 ZHX3 POLQ PML	3.60e-04	198	39	4	5814_UP
Drug	Triflusal [322-79-2]; Up 200; 16.2uM; MCF7; HT_HG-U133A	HIPK2 NPHS1 SLCO1C1 PML	3.60e-04	198	39	4	2867_UP
Drug	Bromocryptine mesylate [22260-51-1]; Up 200; 5.4uM; MCF7; HT_HG-U133A	PDE12 SLCO1C1 PML SCAPER	3.60e-04	198	39	4	1507_UP
Drug	Dizocilpine maleate [77086-22-7]; Down 200; 11.8uM; PC3; HT_HG-U133A	HIPK2 EDEM3 MLH3 PML	3.60e-04	198	39	4	2069_DN
Drug	Pipenzolate bromide [125-51-9]; Down 200; 9.2uM; PC3; HT_HG-U133A	PHC3 EYA4 PML SCAPER	3.67e-04	199	39	4	4484_DN
Drug	Dropropizine (R,S) [17692-31-8]; Up 200; 17uM; MCF7; HT_HG-U133A	ZNF75D ZNF141 PML SCAPER	3.67e-04	199	39	4	7429_UP
Drug	Nitrofurantoin [67-20-9]; Up 200; 16.8uM; HL60; HT_HG-U133A	PHC3 MLH3 PDE12 PML	3.67e-04	199	39	4	2341_UP
Drug	Karakoline [39089-30-0]; Down 200; 10.6uM; HL60; HT_HG-U133A	HIPK2 MLH3 SLCO1C1 PML	3.67e-04	199	39	4	2203_DN
Drug	Catechin-(+,-) hydrate [7295-85-4]; Up 200; 13.8uM; PC3; HT_HG-U133A	ADGRB3 ZNF141 SLCO1C1 PML	3.67e-04	199	39	4	4255_UP
Drug	Crotamiton [483-63-6]; Up 200; 19.6uM; PC3; HT_HG-U133A	ZHX3 DLGAP1 EYA4 CD4	3.67e-04	199	39	4	4628_UP
Drug	Levodopa [59-92-7]; Up 200; 20.2uM; MCF7; HT_HG-U133A	NPHS1 PHC3 PTGER2 SCAPER	3.67e-04	199	39	4	1472_UP
Drug	Palmatine chloride [3486-67-7]; Up 200; 10.4uM; MCF7; HT_HG-U133A	HIPK2 PTGER2 CCDC33 SCAPER	3.67e-04	199	39	4	4957_UP
Drug	nordihydroguaiaretic acid; Up 200; 1uM; HL60; HT_HG-U133A	HYAL4 EYA4 PML CCDC33	3.67e-04	199	39	4	2683_UP
Drug	Sulfamerazine [127-79-7]; Down 200; 15.2uM; MCF7; HT_HG-U133A	ZHX3 PHC3 PTGER2 PML	3.67e-04	199	39	4	3616_DN
Drug	Lobeline alpha (-) hydrochoride [134-63-4]; Down 200; 10.6uM; PC3; HT_HG-U133A	ZNF141 MLH3 PDE12 PML	3.67e-04	199	39	4	5784_DN
Drug	CP-690334-01 [459212-38-5]; Down 200; 1uM; PC3; HT_HG-U133A	ZNF75D ZHX3 PHC3 PDE12	3.67e-04	199	39	4	4561_DN
Drug	Carbenoxolone disodium salt [7421-40-1]; Down 200; 6.6uM; HL60; HT_HG-U133A	PHC3 DLGAP1 PDE12 CCDC33	3.74e-04	200	39	4	3014_DN
Drug	Chlorpropamide [94-20-2]; Up 200; 14.4uM; MCF7; HT_HG-U133A	ZHX3 EYA4 SLCO1C1 PML	3.74e-04	200	39	4	5391_UP
Drug	Pancuronium bromide [15500-66-0]; Up 200; 5.4uM; MCF7; HT_HG-U133A	HIPK2 NPHS1 PML SCAPER	3.74e-04	200	39	4	7329_UP
Drug	rosiglitazone; Down 200; 10uM; MCF7; HT_HG-U133A	HIPK2 ZHX3 PML SCAPER	3.74e-04	200	39	4	5230_DN
Drug	Tranexamic acid [1197-18-8]; Up 200; 25.4uM; PC3; HT_HG-U133A	CD4 PML CCDC33 SCAPER	3.74e-04	200	39	4	5762_UP
Disease	cerebral palsy (implicated_via_orthology)	AGAP11 AGAP7P AGAP4 AGAP6	4.37e-10	10	37	4	DOID:1969 (implicated_via_orthology)
Disease	Alzheimer disease, gastroesophageal reflux disease	ADGRB3 ERCC1 EYA4 PTGER2	1.88e-04	228	37	4	EFO_0003948, MONDO_0004975
Disease	Toxic Epidermal Necrolysis	PML NEDD4	6.08e-04	29	37	2	C0014518
Disease	Mycoplasma-Induced Stevens-Johnson Syndrome	PML NEDD4	6.08e-04	29	37	2	C3658301
Disease	Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum	PML NEDD4	6.08e-04	29	37	2	C3658302
Disease	Drug-Induced Stevens Johnson Syndrome	PML NEDD4	6.08e-04	29	37	2	C1274933
Disease	Stevens-Johnson Syndrome	PML NEDD4	6.51e-04	30	37	2	C0038325
Disease	ejection fraction measurement	DLGAP1 PTGER2	1.34e-03	43	37	2	EFO_0005527
Disease	waist-hip ratio	BPTF ZHX3 EYA4 CREB3L3 PML PDZRN4	3.91e-03	1226	37	6	EFO_0004343
Disease	obsolete aging	ZNF106 CREB3L3 PDZRN4	5.12e-03	279	37	3	GO_0007568
Disease	Neurodevelopmental Disorders	DLGAP1 KMT2E	6.09e-03	93	37	2	C1535926

Protein segments in the cluster

Peptide	Gene	Start	Entry
CESSKSKSQLTSQSK	AGAP4	426	Q96P64
QSCESSKSKSQLTSQ	AGAP11	311	Q8TF27
EKNNQSSKAVTSVTS	CCDC33	271	Q8N5R6
VQSTSKSAQTGTCVA	CREB3L3	311	Q68CJ9
TKNVKTTTNCFSSNT	ADGRG4	1781	Q8IZF6
GQTQTHNKSICTTTT	ADGRB3	931	O60242
TQVSETSVSTCKSSK	ALPK2	866	Q86TB3
TSVSTCKSSKDGNSV	ALPK2	871	Q86TB3
IQSSTVSSCITTYKK	DLGAP1	526	O14490
KQTVVSSTENCAKST	BPTF	1736	Q12830
CESSKSKSQLTSQSE	AGAP6	426	Q5VW22
TSTKAKTTEQGCSAE	PDZRN4	791	Q6ZMN7
QTENKNVTLSCVSKS	NPHS1	351	O60500
STVSKQRKNVISCVT	HIPK2	906	Q9H2X6
SSENVNKKSSCLQIS	NEDD4	76	P46934
STTNQSISKKNTTSE	EDEM3	501	Q9BZQ6
QSSESSVKFSCKLTN	CDKN2AIP	416	Q9NXV6
ATCTTKVKANSVKQE	CAND1	1151	Q86VP6
TECLTTVKSVNKTDS	ERCC1	236	P07992
SKTHSNSNTTENCVI	MLH3	951	Q9UHC1
QSTKDSSKRICVANT	PDE12	441	Q6L8Q7
ATQTSCSTQSDASKQ	PTGER2	341	P43116
STAKTEVKTECKDTQ	KMT2E	606	Q8IZD2
STSQTQSLTICHNKT	PHC3	236	Q8NDX5
QSLTICHNKTTVTSS	PHC3	241	Q8NDX5
CHNKTTVTSSKISQR	PHC3	246	Q8NDX5
SVKKTCTESDVSQSQ	EYA4	11	O95677
SQSKNVTCQATSVVS	POLQ	1141	O75417
ASKANCTKVKQFVSS	HYAL4	346	Q2M3T9
TVELTCTASQKKSIQ	CD4	36	P01730
CESSKSKSQLTSQSE	AGAP7P	426	Q5VUJ5
KTTKQSTAVDCKITS	SCAPER	61	Q9BY12
ESDTCSSQKTEVSTV	OPN1SW	326	P03999
NQKKSDSSSASVCSI	PWWP2A	571	Q96N64
EDVSNTTTAQKRKCS	PML	466	P29590
KINSSSVCVSSISEN	TMIGD1	81	Q6UXZ0
KSKISNECEVDTSSS	SLCO1C1	171	Q9NYB5
QCKASVKVVSKFSNS	ZNF141	146	Q15928
STSEIQTSGCEVSKK	ZNF75D	291	P51815
TVCSNTTSAVKVVNA	ZHX3	461	Q9H4I2
KSSVQEECVSTISSS	TRMT10C	71	Q7L0Y3
SQTTKQADTATSKVS	ZNF106	321	Q9H2Y7